1. Do we really need prognostic factors for breast cancer?

   • Gary M. Clark

   Plenary lecture, 15th Annual San Antonio Breast Cancer Symposium Pages: 117 - 126

2. Effect of two 4-hydroxyandrostenedione doses on serum insulin-like growth factor I levels in advanced breast cancer

   • Leonardo Ferrari
   • Nicoletta Zilembo
   • Anna Maria Cerrotta

   Report Pages: 127 - 132

3. Phase II study of weekly mitoxantrone, 5-fluorouracil, and leucovorin in metastatic breast cancer

   • Lazzaro Repetto
   • Loredana Miglietta
   • Riccardo Rosso

   Report Pages: 133 - 137

4. Expression of epidermal growth factor receptor (EGFR) in non-affected and tumorous mammary tissue of female dogs

   • G. R. Rutteman
   • J. A. Foekens
   • W. Misdorp

   Report Pages: 139 - 146

5. Demonstration of gene-amplification by PCR in archival paraffin-embedded breast cancer tissue

   • Ulf Lönn
   • Sigrid Lönn
   • Björn Stenkvist

   Report Pages: 147 - 152

6. Patterns of cyclic AMP binding in normal human breast

   • S. Battersby
   • T. J. Anderson
   • W. R. Miller

   Report Pages: 153 - 158

7. 4-Hydroxytamoxifen, an active metabolite of tamoxifen, does not alter the radiation sensitivity of MCF-7 breast carcinoma cells irradiatedin vitro

   • Jann N. Sarkaria
   • Elizabeth M. Miller
   • R. Timothy Mulcahy

   Report Pages: 159 - 165

8. p53Val135 temperature sensitive mutant suppresses growth of human breast cancer cells

   • Daniel Eliyahu
   • Steve Evans
   • Marc Lippman

   Report Pages: 167 - 177

9. Quantitative analysis of mutant p53 protein in breast tumor cytosols and study of its association with other biochemical prognostic indicators in breast cancer

   • Michael A. Levesque
   • Eleftherios P. Diamandis
   • Donald J. A. Sutherland

   Report Pages: 179 - 195

10. Immunosuppressive acidic protein serum levels in breast cancer patients in a reference to CA 15-3 levels

    • Arnon D. Cohen
    • Yehuda Shoenfeld
    • Yoram Cohen

    Brief communication Pages: 197 - 200

11. The incidence of hepatocellular carcinoma in US white women with breast cancer after the introduction of tamoxifen in 1977

    • Kathrin Mühlemann
    • Linda S. Cook
    • Noel S. Weiss

    Brief communication Pages: 201 - 204

12. Phase II trial of 5-fluorouracil and folinic acid in the treatment of advanced breast cancer

    • Sheldon Fine
    • Charles Erlichman
    • Tahany Gadalla

    Brief communication Pages: 205 - 209